PO Box 83395

Gaithersburg, MD 20883




(301) 525-2321


  • White LinkedIn Icon


August 15, 2018

This week, the FDA approved Alnylam Pharmaceuticals’ ONPATTRO™ (patisiran), an innovative RNA interference (RNAi) therapy to treat polyneuropathy of hATTR amyloidosis. As you may imagine, this advanced, Nobel Prize-winning technology comes at a premium price, over $400...

July 24, 2018

Skeptics of bundled payments, even if they are not proponents of line-item payments, scored a victory last week with the publication of a study in the New England Journal of Medicine that determined no significant difference in costs or outcomes in a Medicare bundled p...

February 23, 2018

The first or second question anyone asks during a social event, or on the sidelines of a middle school soccer game, is what I do for a living. After I give my well-rehearsed elevator speech of the importance of drug or device reimbursement, the person speaking with me...

September 11, 2017

Let's discuss payers reimbursing for digital health applications

April 25, 2017

Citizens, watchdogs, and legislators again are homing in on drug developers and marketers for their high-priced products. As trade organizations and even some who disapprove of industry practices note, this negative impression evolved from the actions of a few, not the...

March 6, 2017

Maryland’s Senate Finance Committee is considering bringing the “Expensive Drugs” bill (SB 437) to the floor for deliberation and a vote. This bill is misguided and seems to accomplish nothing to help the citizens of Maryland pay less for “expensive drugs” or in helpin...

October 19, 2015


In my last (and first) blog, I talked about the concepts that CMS would like to test in Phase I of its proposed rule on Part B Drugs. CMS expressed concern that spending $21 billion a year on drugs administered in physician offices and other outpatient settings is to...

October 18, 2015

There’s no better time or way to jump into Blogworld than to postulate on a topic of great interest to the industry and one that I know a little bit about, Medicare’s proposed Part B Drug Rule. In March of this year, the Centers for Medicare and Medicaid Services (CMS)...

Please reload